Dr Prakash.I
 What’s Known On This Subject:

Acid-suppressive drugs could facilitate the onset of
infections in adults and children. Evidence for efficacy
is weak in newborns, esp. if preterm.
 What This Study Adds:
First prospective study demonstrating an association
between the use of ranitidine and infections, NEC, and
fatal outcome in VLBW newborns. Caution is
advocated in using ranitidine in newborns.
Introduction
 Infections are a common cause of morbidity and

mortality in premature infants.
 Gastric juice is a major nonimmune defense
mechanism against infections.
 Treatment with inhibitors of gastric acid secretion
leads to insufficient elimination of several ingested
pathogens.
 Many studies show that these drugs facilitate the onset
of infections in adults and children.
 There is evidence of an increased risk of infections and

NEC related to the use of histamine-2 receptor (H2-R)
blockers and proton pump inhibitors in neonates.
 Not approved by the US FDA for use in neonates

because of the perceived safety and potential benefit.
 Most common indications: prophylaxis or therapy of

stress ulcers and GERD,
 Efficacy in preterm infants is still debated.
Methods
Populations
 Birth weight (between 401 and 1500 g) /gestational age
(between 24 and 32 weeks)
 From January 2006 to June 2007.
 Exclusion criteria =immunodeficiency, malformations,
evidence of infections or NEC before enrollment, critical
conditions (blood pH < 6.8, or hypoxia with persistent
bradycardia for at least 1 hour), ranitidine therapy for fewer
than 7 days, and hospitalization for fewer than 8 weeks.
 Indications, dosage, and duration of ranitidine treatment
were decided by the caregivers, who were unaware of the
study aims.
 Approved by the Ethics Committee. Written consent was
obtained from the parents.
Outcome Measures
 Primary outcome= the rate of infections in newborns

exposed or not exposed to ranitidine treatment.
 Secondary outcomes=occurrence of NEC (Bell stage

>II), mortality, and duration of hospital stay.
•Sepsis = presence of signs suggestive of infection

associated with a positive blood culture.
•Pneumonia =presence of clinical signs (progressive
increase in oxygen requirement, bradycardia, and/or
apnea, tachypnea, or dyspnea) associated with positive
culture of endotracheal aspirate (when patients were
intubated) and with pathologic signs at chest
examination and radiograph.
•Urinary tract infections (UTI) =when a positive urine
culture together with clinical findings, such as sign of
sepsis, weight loss, or growth retardation were
present. Diagnosis of NEC and Bell stage were decided on
the basis of standardized clinical and radiologic criteria.
Data Collection
 Researchers enrolled are unaware of the study aims.
 Collected data’s : GA, BW, Apgar score, CRIB score,

occurrence of infections or NEC, antibiotic therapy,
indications for and dosage of ranitidine treatment,
duration of ranitidine treatment, modality and
duration of mechanical ventilation, oxygen therapy,
presence and duration of central vascular access, IVH,
PDA, time to reach full enteral feeding; results of
microbiological, radiologic, and laboratory tests;
diagnosis of stress-induced peptic disease and of
GERD, time to discharge, or death.
•Enteral feeding started on day 1 of life at 10 mL/kg per

day in 8 to 12 feeds, using preterm formula in all stable
infants.
•Maternal unfortified milk was given when available.
•Aspirate residue and abdominal circumference were

measured before each feed.
•In absence of food intolerance during the previous 24

hours, the total amount of enteral nutrition was
increased by 10 to 20 mL/kg per day.
• Enteral nutrition was discontinued if erythematic

abdominal wall, absence of bowel sounds, or blood in
the stools or in aspirates, associated with radiologic
markers of NEC-Bell stage higher than I were noted.
• Parenteral nutrition given through a central vascular
access in infants to maintain an adequate intake of
fluids, electrolytes, and nutrients, until full enteral
feeding (120 kcal/kg per day) was reached.
• Fluids were started at 70 to 100 mL/kg per day with
increments of 10 to 20 mL/kg per day until 150 to 180
mL/kg per day.
Ranitidine is associated with infections, necrotizing enterocolitis
Ranitidine is associated with infections, necrotizing enterocolitis
Statistics
 Minimum sample size of 90 patients for each group to obtain a








power of the study of 90% (type 1 error = 0.05 with a 2-tailed test).
The Kolmogorov-Smirnov test was used to determine whether
variables were normally distributed. For continuous variables,
groups were compared using the t test, and the MannWhitney U test.
The χ2 test and Fisher’s exact test were used for categorical
variables.
The McNemar test was used to detect differences before and after
the use of ranitidine.
A multivariate analysis using binary logistic regression analysis
to evaluate whether GA, BW, sex, Apgar score, CRIB score, IVH,
PDA, central vascular access, or mechanical ventilation affected
the prescription of ranitidine.
Statistical analysis was performed by using SPSS, version 16.0 for
Windows (SPSS Inc., Chicago, IL).
Ranitidine is associated with infections, necrotizing enterocolitis
Results
 Total enrolled=309 VLBW newborns.

 35 infants were excluded because of critical clinical

conditions (10 patients), malformations (8 patients),
sepsis before enrollment (12 patients), and length of
hospitalization fewer than 8 weeks (5 patients).
 Obtained data from 274 infants. 91 of these infants
had received ranitidine (42 as prophylaxis of stressinduced peptic disease; 49 because of suspected
GERD), and 183 represented the control cohort of
newborns not exposed to ranitidine.
 The diagnosis of GERD was made based on clinical

criteria without pH-metry or endoscopy.
 The characteristics did not differ between patients
receiving ranitidine for prophylaxis of stress-induced
peptic disease and patients receiving ranitidine for
GERD.
Multivariate binary logistic regression analysis revealed that the prescription of
ranitidine by physicians was not affected by
features

OR

CI

P

GA

0.846

0.694-1.031

0.098

BW

0.999

0.997–1.001

0.444

Sex

2.031

0.972–4.243,

0.060

Apgar score

1 minute: 0.863,
5 minute: 0.905,

1 minute: 0.653–
1.141, 5 minute:
0.486–1.687

1 minute:.301
5 minute:0.754

CRIB Score

1.008

0.869–1.169

0.918

IVH

2.127

0.635–7.124

0.221

PDA

0.755

0.323–1.764

0 .516

Central vascular
access

1.004

0.960–1.050

0 .855

Mechanical
ventilation

0.940

0.850–1.040

0.233

mechanical ventilation (OR 0.940, 95% CI 0.850–1.040, P = .233).
309 cases
35 cases excluded
274 cases

91 cases
(received Ranitidine)

183 cases
(control cohort not exposed
to ranitidine)
 Newborns treated with ranitidine had more infections

(OR 5.5, 95% CI 2.9–10.4, P < .001), i.e sepsis,
pneumonia, and UTI, than newborns not treated with
ranitidine.
 Mean time to infection after starting ranitidine
treatment :17.9 days (95% CI 13.0–22.8).
 In Infants treated with ranitidine, there was a slight
but not significant increase in drug dosage in subjects
presenting infections (intravenous 2.43 mg/kg per day,
95% CI 1.84–3.03 vs 1.85 mg/kg per day; 95% CI 1.55–
2.16, P = .052; enteral route 11.44 mg/kg per day; 95% CI
8.08–14.80 vs 9.82 mg/kg per day; 95% CI 8.22–11.42, P =
.310).
 Risk of infections was unrelated to the duration of

ranitidine treatment. NEC was (P = .003) more frequent
(OR 6.6; 95% CI 1.7–25.0) in VLBW infants treated with
ranitidine (9.8%) than in those not exposed (1.6%).
 Risk of NEC was unrelated to the dosage or duration of
ranitidine therapy. Twelve patients died during the
study.
 Mortality rate -significantly higher in newborns
receiving ranitidine (9.9% vs 1.6%, P = .003), and
hospitalization was significantly longer in those
exposed to ranitidine (median 52 days, range 43 vs 36
days, range 22, P < .001).
Discussion
 Graham et al, in a RCT of the effects of hand hygiene

practices on hospital-acquired late-onset gram-negative
sepsis, showed that the inhibitors of gastric acid secretion
entailed an increased risk of infection in LBW newborns.
In this study, the prescription of ranitidine was not
influenced by the severity of the patient’s clinical
condition.
 Bianconi et al reported an association between ranitidine
use and the risk of late-onset sepsis, but they used a
retrospective design and the number of newborns enrolled
was very small.
 In a RCT, Stoll et al evaluated the relationship between

postnatal steroid exposure and late-onset sepsis in
VLBW infants. They observed that treatment with
dexamethasone was associated with an increased risk
of sepsis and meningitis.
 During the analysis of the factors, the authors found
an increased use of H2R blocker therapy in patients
developing infections.
 In a prospective study, Beck-Sague et al reported a
fourfold increase in the risk of bloodstream infection
in neonates who received H2R blockers; in this case,
neonates who developed infection were more severely
ill and were of lower GA on admission than infants not
developing these infections.
 Gastric juice and intestinal microflora : major defense

factors against invasion of the gut by microorganisms.
 Gastric juice kills bacteria within 15 minutes when the
pH is < 3.0.
 Changes in the composition of the intestinal
microflora are associated with the development of
sepsis and NEC. Thus, it is conceivable that
hypochlorhydria could contribute to the abnormal
immune activation observed during NEC.
 The direct effect exerted by ranitidine on the immune
system could influence the risk for NEC in neonates.
Activation of H2R alters the production of
inflammatory cytokines and disrupts the Th1–Th2
balance, thereby leading to insufficient control of
infections and inflammation at the intestinal level.
 There is no clear evidence that H2R blockers are beneficial in

many clinical conditions typical of neonatal age, such as apnea.
 The results suggest that
Ranitidine to be administered after a careful consideration of
the
risk-benefit ratio.
An increased mortality in newborns receiving ranitidine.
Mortality in ranitidine exposed group was 6 times higher
This suggests that caution should be exercised regarding the
administration of ranitidine
 The administration of ranitidine in VLBW infants increases
health care costs due to prolonged hospital care.
 The median cost of hospitalization is about $1250 per day for a
VLBW infant. The difference in median duration of
hospitalization between the 2 groups was 20 days, thereby
resulting in a reduction of about $25 000 per patient.
Conclusion
 Ranitidine should be administered with care in

preterm infants because of the risk of severe infectious
disease, NEC, and fatal outcome.
 Further studies are necessary to investigate the
pathogenesis of these effects and the possible
prophylactic measures that could be taken to prevent
them.
Thank you

More Related Content

DOCX
Pancreatitis - enteral vs paraenteral nutrition
PPTX
Lactobacillus journal club
PPTX
Point-of-Care Ultrasound Diagnosis an Asset for IBD Patients
PPTX
Drug Allergy Testing How and is it important?
PPTX
Research to practice - 5 papers of interest
PPTX
What's new in c. diff
PPTX
Antibacterial therapy in COVID-19 patients - an evidence based guideline
PPTX
COVID in Pregnancy
Pancreatitis - enteral vs paraenteral nutrition
Lactobacillus journal club
Point-of-Care Ultrasound Diagnosis an Asset for IBD Patients
Drug Allergy Testing How and is it important?
Research to practice - 5 papers of interest
What's new in c. diff
Antibacterial therapy in COVID-19 patients - an evidence based guideline
COVID in Pregnancy

What's hot (20)

PPT
Management Of The Febrile Infant
PPTX
Helicobacter Pylori Infection: Management in 2020
PDF
Tratamiento con MRF en pacientes con infecciones urinarias
PDF
Don't just do something, sit there: the asymptomatic child with suspected ing...
PDF
4 kahi lower gi
PPTX
Antimicrobial Stewardship (PROA) Journal Watch
PPTX
Rifaximin for Recurrent Clostridium Difficile Infections
PDF
Consensus Guidelines: Childhood Convulsive Status Epilepticus (Indian Pediatr...
PDF
RSV Prev CE Analysis
PPTX
GI CANCER SCREENING
PPTX
Efficacy and safety of immunomodulators in pediatric age - Slideset by Profes...
PPTX
Gi presentations of non gi disorders how to avoid pitfalls
PPTX
Treatment of Pediatric Tuberculosis
PDF
05NTD 2022 - UPDATES IN VECTOR CONTROL IN MALAYSIA: What is new?
PPTX
Understanding Antibiotics in Critically Ill Surgical Patients
PPTX
Hpylori2020new
PDF
Doctor's Data Inc GI Pathogen Reference Guide
PDF
01NTD 2022 - Management of Dengue in Primary Care
PDF
COVID-19 Vaccination in Patients Requiring Palliative Care
DOCX
MUE - Parenteral Nutrition
Management Of The Febrile Infant
Helicobacter Pylori Infection: Management in 2020
Tratamiento con MRF en pacientes con infecciones urinarias
Don't just do something, sit there: the asymptomatic child with suspected ing...
4 kahi lower gi
Antimicrobial Stewardship (PROA) Journal Watch
Rifaximin for Recurrent Clostridium Difficile Infections
Consensus Guidelines: Childhood Convulsive Status Epilepticus (Indian Pediatr...
RSV Prev CE Analysis
GI CANCER SCREENING
Efficacy and safety of immunomodulators in pediatric age - Slideset by Profes...
Gi presentations of non gi disorders how to avoid pitfalls
Treatment of Pediatric Tuberculosis
05NTD 2022 - UPDATES IN VECTOR CONTROL IN MALAYSIA: What is new?
Understanding Antibiotics in Critically Ill Surgical Patients
Hpylori2020new
Doctor's Data Inc GI Pathogen Reference Guide
01NTD 2022 - Management of Dengue in Primary Care
COVID-19 Vaccination in Patients Requiring Palliative Care
MUE - Parenteral Nutrition
Ad

Viewers also liked (20)

ODP
Generic Zantac for Treatment of Duodenal and Gastric Ulcers
PPTX
Kasus Drugs related problem 2016
PPTX
cimetidine
PPTX
PPTX
Generic Zantac To Treat Stomach Ulcer
ODP
Flagyl (Metronidazole Tablets)
PPT
H2 antagonist and ppi
PPTX
Dexamethasone
PPTX
Antihistamines
PPT
peptic ulcer
PPTX
PDF
Voltaren campaign || A.TANTAWY
PPTX
Peptic ulcer treatment
PPT
Peptic Ulcer Disease.Ppt.Fmdrl
PPT
Peptic ulcer disease
PDF
Dispercam Marketing Plan @AxTantawy
PPTX
Peptic ulcer
PPT
Peptic ulcer disease
PPT
Panadol ppt
Generic Zantac for Treatment of Duodenal and Gastric Ulcers
Kasus Drugs related problem 2016
cimetidine
Generic Zantac To Treat Stomach Ulcer
Flagyl (Metronidazole Tablets)
H2 antagonist and ppi
Dexamethasone
Antihistamines
peptic ulcer
Voltaren campaign || A.TANTAWY
Peptic ulcer treatment
Peptic Ulcer Disease.Ppt.Fmdrl
Peptic ulcer disease
Dispercam Marketing Plan @AxTantawy
Peptic ulcer
Peptic ulcer disease
Panadol ppt
Ad

Similar to Ranitidine is associated with infections, necrotizing enterocolitis (20)

PPTX
Gastroesophageal Reflux in Preterm Neonate
PPTX
PPTX
Journal club on early feeding versusu late feeding in newborns
PPTX
Feeding intolerance in preterm infants.pptx
PPT
Neonatal Sepsis paediatrics Nursing .ppt
PPTX
Juring gizi : AminoAcid Formula in Preterm
PPT
Schanler nec feb 2010 handout
PDF
Nursing Care Plan - Bang Di Phan Nguyen - 8m/o
PPTX
journal poush journal club journal articles
PPTX
neonatal sepsis
PPT
Rational Mangement of Neonatal-Sepsis .ppt
PPTX
NEC in newborn
PDF
Gerd in infants
PPTX
GERD, Dr Falakha .pptx
PPTX
GERD, Dr Falakha .pptx
PPT
Alimentary prophylaxis in icu
PPT
EBM Sangli 2jhhjuh huhuhuhjhj hjhjh014.ppt
PPTX
intensive care of paediatrics resuscitation, stabilization and monitoring.pptx.
PPTX
Early Onset Neonatal Sepsis questions and controversies
PPTX
use of antimicrobials in neonatal practice
Gastroesophageal Reflux in Preterm Neonate
Journal club on early feeding versusu late feeding in newborns
Feeding intolerance in preterm infants.pptx
Neonatal Sepsis paediatrics Nursing .ppt
Juring gizi : AminoAcid Formula in Preterm
Schanler nec feb 2010 handout
Nursing Care Plan - Bang Di Phan Nguyen - 8m/o
journal poush journal club journal articles
neonatal sepsis
Rational Mangement of Neonatal-Sepsis .ppt
NEC in newborn
Gerd in infants
GERD, Dr Falakha .pptx
GERD, Dr Falakha .pptx
Alimentary prophylaxis in icu
EBM Sangli 2jhhjuh huhuhuhjhj hjhjh014.ppt
intensive care of paediatrics resuscitation, stabilization and monitoring.pptx.
Early Onset Neonatal Sepsis questions and controversies
use of antimicrobials in neonatal practice

More from CMCH,Vellore (10)

PPTX
Congenital chloride diarrhea (case presentation)
PPTX
Chloride losing diarrhoea prakash
PPTX
transfusion associated malaria in neonates
PPTX
case presentation on transfusion associated malaria
PPTX
Complex congenital heart disease
PPTX
Ranitidine is associated with infections, necrotizing enterocolitis
PPTX
Transitional hypothermia in preterm newborns
PPTX
Transitional hypothermia in preterm newborns
PPT
High risk infant
PPT
Neonatal sepsis
Congenital chloride diarrhea (case presentation)
Chloride losing diarrhoea prakash
transfusion associated malaria in neonates
case presentation on transfusion associated malaria
Complex congenital heart disease
Ranitidine is associated with infections, necrotizing enterocolitis
Transitional hypothermia in preterm newborns
Transitional hypothermia in preterm newborns
High risk infant
Neonatal sepsis

Recently uploaded (20)

PPT
intrduction to nephrologDDDDDDDDDy lec1.ppt
PPTX
Peripheral Arterial Diseases PAD-WPS Office.pptx
PPTX
Journal Article Review - Ankolysing Spondylitis - Dr Manasa.pptx
PPTX
PARASYMPATHETIC NERVOUS SYSTEM and its correlation with HEART .pptx
PPTX
DIARRHOEA IN CHILDREN presented to COG.ppt
PDF
Nursing manual for conscious sedation.pdf
PPTX
Sanitation and public health for urban regions
PPTX
SUMMARY OF EAR, NOSE AND THROAT DISORDERS INCLUDING DEFINITION, CAUSES, CLINI...
PPTX
Method of organizing health promotion and education and counselling activitie...
PPTX
HOP RELATED TO NURSING EDUCATION FOR BSC
PDF
NCM-107-LEC-REVIEWER.pdf 555555555555555
PPTX
Assessment of fetal wellbeing for nurses.
PPTX
ARTHRITIS and Types,causes,pathophysiology,clinicalanifestations,diagnostic e...
PPTX
Pharynx and larynx -4.............pptx
PPTX
Hyperthyroidism, Thyrotoxicosis, Grave's Disease with MCQs.pptx
PPTX
IND is a submission to the food and drug administration (FDA), requesting per...
PPTX
01. cell injury-2018_11_19 -student copy.pptx
PDF
Approach to dyspnea/shortness of breath (SOB)
PPTX
Tuberculosis : NTEP and recent updates (2024)
PPTX
AWMI case presentation ppt AWMI case presentation ppt
intrduction to nephrologDDDDDDDDDy lec1.ppt
Peripheral Arterial Diseases PAD-WPS Office.pptx
Journal Article Review - Ankolysing Spondylitis - Dr Manasa.pptx
PARASYMPATHETIC NERVOUS SYSTEM and its correlation with HEART .pptx
DIARRHOEA IN CHILDREN presented to COG.ppt
Nursing manual for conscious sedation.pdf
Sanitation and public health for urban regions
SUMMARY OF EAR, NOSE AND THROAT DISORDERS INCLUDING DEFINITION, CAUSES, CLINI...
Method of organizing health promotion and education and counselling activitie...
HOP RELATED TO NURSING EDUCATION FOR BSC
NCM-107-LEC-REVIEWER.pdf 555555555555555
Assessment of fetal wellbeing for nurses.
ARTHRITIS and Types,causes,pathophysiology,clinicalanifestations,diagnostic e...
Pharynx and larynx -4.............pptx
Hyperthyroidism, Thyrotoxicosis, Grave's Disease with MCQs.pptx
IND is a submission to the food and drug administration (FDA), requesting per...
01. cell injury-2018_11_19 -student copy.pptx
Approach to dyspnea/shortness of breath (SOB)
Tuberculosis : NTEP and recent updates (2024)
AWMI case presentation ppt AWMI case presentation ppt

Ranitidine is associated with infections, necrotizing enterocolitis

  • 2.  What’s Known On This Subject: Acid-suppressive drugs could facilitate the onset of infections in adults and children. Evidence for efficacy is weak in newborns, esp. if preterm.  What This Study Adds: First prospective study demonstrating an association between the use of ranitidine and infections, NEC, and fatal outcome in VLBW newborns. Caution is advocated in using ranitidine in newborns.
  • 3. Introduction  Infections are a common cause of morbidity and mortality in premature infants.  Gastric juice is a major nonimmune defense mechanism against infections.  Treatment with inhibitors of gastric acid secretion leads to insufficient elimination of several ingested pathogens.  Many studies show that these drugs facilitate the onset of infections in adults and children.
  • 4.  There is evidence of an increased risk of infections and NEC related to the use of histamine-2 receptor (H2-R) blockers and proton pump inhibitors in neonates.  Not approved by the US FDA for use in neonates because of the perceived safety and potential benefit.  Most common indications: prophylaxis or therapy of stress ulcers and GERD,  Efficacy in preterm infants is still debated.
  • 5. Methods Populations  Birth weight (between 401 and 1500 g) /gestational age (between 24 and 32 weeks)  From January 2006 to June 2007.  Exclusion criteria =immunodeficiency, malformations, evidence of infections or NEC before enrollment, critical conditions (blood pH < 6.8, or hypoxia with persistent bradycardia for at least 1 hour), ranitidine therapy for fewer than 7 days, and hospitalization for fewer than 8 weeks.  Indications, dosage, and duration of ranitidine treatment were decided by the caregivers, who were unaware of the study aims.  Approved by the Ethics Committee. Written consent was obtained from the parents.
  • 6. Outcome Measures  Primary outcome= the rate of infections in newborns exposed or not exposed to ranitidine treatment.  Secondary outcomes=occurrence of NEC (Bell stage >II), mortality, and duration of hospital stay.
  • 7. •Sepsis = presence of signs suggestive of infection associated with a positive blood culture. •Pneumonia =presence of clinical signs (progressive increase in oxygen requirement, bradycardia, and/or apnea, tachypnea, or dyspnea) associated with positive culture of endotracheal aspirate (when patients were intubated) and with pathologic signs at chest examination and radiograph. •Urinary tract infections (UTI) =when a positive urine culture together with clinical findings, such as sign of sepsis, weight loss, or growth retardation were present. Diagnosis of NEC and Bell stage were decided on the basis of standardized clinical and radiologic criteria.
  • 8. Data Collection  Researchers enrolled are unaware of the study aims.  Collected data’s : GA, BW, Apgar score, CRIB score, occurrence of infections or NEC, antibiotic therapy, indications for and dosage of ranitidine treatment, duration of ranitidine treatment, modality and duration of mechanical ventilation, oxygen therapy, presence and duration of central vascular access, IVH, PDA, time to reach full enteral feeding; results of microbiological, radiologic, and laboratory tests; diagnosis of stress-induced peptic disease and of GERD, time to discharge, or death.
  • 9. •Enteral feeding started on day 1 of life at 10 mL/kg per day in 8 to 12 feeds, using preterm formula in all stable infants. •Maternal unfortified milk was given when available. •Aspirate residue and abdominal circumference were measured before each feed. •In absence of food intolerance during the previous 24 hours, the total amount of enteral nutrition was increased by 10 to 20 mL/kg per day.
  • 10. • Enteral nutrition was discontinued if erythematic abdominal wall, absence of bowel sounds, or blood in the stools or in aspirates, associated with radiologic markers of NEC-Bell stage higher than I were noted. • Parenteral nutrition given through a central vascular access in infants to maintain an adequate intake of fluids, electrolytes, and nutrients, until full enteral feeding (120 kcal/kg per day) was reached. • Fluids were started at 70 to 100 mL/kg per day with increments of 10 to 20 mL/kg per day until 150 to 180 mL/kg per day.
  • 13. Statistics  Minimum sample size of 90 patients for each group to obtain a     power of the study of 90% (type 1 error = 0.05 with a 2-tailed test). The Kolmogorov-Smirnov test was used to determine whether variables were normally distributed. For continuous variables, groups were compared using the t test, and the MannWhitney U test. The χ2 test and Fisher’s exact test were used for categorical variables. The McNemar test was used to detect differences before and after the use of ranitidine. A multivariate analysis using binary logistic regression analysis to evaluate whether GA, BW, sex, Apgar score, CRIB score, IVH, PDA, central vascular access, or mechanical ventilation affected the prescription of ranitidine. Statistical analysis was performed by using SPSS, version 16.0 for Windows (SPSS Inc., Chicago, IL).
  • 15. Results  Total enrolled=309 VLBW newborns.  35 infants were excluded because of critical clinical conditions (10 patients), malformations (8 patients), sepsis before enrollment (12 patients), and length of hospitalization fewer than 8 weeks (5 patients).  Obtained data from 274 infants. 91 of these infants had received ranitidine (42 as prophylaxis of stressinduced peptic disease; 49 because of suspected GERD), and 183 represented the control cohort of newborns not exposed to ranitidine.
  • 16.  The diagnosis of GERD was made based on clinical criteria without pH-metry or endoscopy.  The characteristics did not differ between patients receiving ranitidine for prophylaxis of stress-induced peptic disease and patients receiving ranitidine for GERD.
  • 17. Multivariate binary logistic regression analysis revealed that the prescription of ranitidine by physicians was not affected by features OR CI P GA 0.846 0.694-1.031 0.098 BW 0.999 0.997–1.001 0.444 Sex 2.031 0.972–4.243, 0.060 Apgar score 1 minute: 0.863, 5 minute: 0.905, 1 minute: 0.653– 1.141, 5 minute: 0.486–1.687 1 minute:.301 5 minute:0.754 CRIB Score 1.008 0.869–1.169 0.918 IVH 2.127 0.635–7.124 0.221 PDA 0.755 0.323–1.764 0 .516 Central vascular access 1.004 0.960–1.050 0 .855 Mechanical ventilation 0.940 0.850–1.040 0.233 mechanical ventilation (OR 0.940, 95% CI 0.850–1.040, P = .233).
  • 18. 309 cases 35 cases excluded 274 cases 91 cases (received Ranitidine) 183 cases (control cohort not exposed to ranitidine)
  • 19.  Newborns treated with ranitidine had more infections (OR 5.5, 95% CI 2.9–10.4, P < .001), i.e sepsis, pneumonia, and UTI, than newborns not treated with ranitidine.  Mean time to infection after starting ranitidine treatment :17.9 days (95% CI 13.0–22.8).  In Infants treated with ranitidine, there was a slight but not significant increase in drug dosage in subjects presenting infections (intravenous 2.43 mg/kg per day, 95% CI 1.84–3.03 vs 1.85 mg/kg per day; 95% CI 1.55– 2.16, P = .052; enteral route 11.44 mg/kg per day; 95% CI 8.08–14.80 vs 9.82 mg/kg per day; 95% CI 8.22–11.42, P = .310).
  • 20.  Risk of infections was unrelated to the duration of ranitidine treatment. NEC was (P = .003) more frequent (OR 6.6; 95% CI 1.7–25.0) in VLBW infants treated with ranitidine (9.8%) than in those not exposed (1.6%).  Risk of NEC was unrelated to the dosage or duration of ranitidine therapy. Twelve patients died during the study.  Mortality rate -significantly higher in newborns receiving ranitidine (9.9% vs 1.6%, P = .003), and hospitalization was significantly longer in those exposed to ranitidine (median 52 days, range 43 vs 36 days, range 22, P < .001).
  • 21. Discussion  Graham et al, in a RCT of the effects of hand hygiene practices on hospital-acquired late-onset gram-negative sepsis, showed that the inhibitors of gastric acid secretion entailed an increased risk of infection in LBW newborns. In this study, the prescription of ranitidine was not influenced by the severity of the patient’s clinical condition.  Bianconi et al reported an association between ranitidine use and the risk of late-onset sepsis, but they used a retrospective design and the number of newborns enrolled was very small.
  • 22.  In a RCT, Stoll et al evaluated the relationship between postnatal steroid exposure and late-onset sepsis in VLBW infants. They observed that treatment with dexamethasone was associated with an increased risk of sepsis and meningitis.  During the analysis of the factors, the authors found an increased use of H2R blocker therapy in patients developing infections.  In a prospective study, Beck-Sague et al reported a fourfold increase in the risk of bloodstream infection in neonates who received H2R blockers; in this case, neonates who developed infection were more severely ill and were of lower GA on admission than infants not developing these infections.
  • 23.  Gastric juice and intestinal microflora : major defense factors against invasion of the gut by microorganisms.  Gastric juice kills bacteria within 15 minutes when the pH is < 3.0.  Changes in the composition of the intestinal microflora are associated with the development of sepsis and NEC. Thus, it is conceivable that hypochlorhydria could contribute to the abnormal immune activation observed during NEC.  The direct effect exerted by ranitidine on the immune system could influence the risk for NEC in neonates. Activation of H2R alters the production of inflammatory cytokines and disrupts the Th1–Th2 balance, thereby leading to insufficient control of infections and inflammation at the intestinal level.
  • 24.  There is no clear evidence that H2R blockers are beneficial in many clinical conditions typical of neonatal age, such as apnea.  The results suggest that Ranitidine to be administered after a careful consideration of the risk-benefit ratio. An increased mortality in newborns receiving ranitidine. Mortality in ranitidine exposed group was 6 times higher This suggests that caution should be exercised regarding the administration of ranitidine  The administration of ranitidine in VLBW infants increases health care costs due to prolonged hospital care.  The median cost of hospitalization is about $1250 per day for a VLBW infant. The difference in median duration of hospitalization between the 2 groups was 20 days, thereby resulting in a reduction of about $25 000 per patient.
  • 25. Conclusion  Ranitidine should be administered with care in preterm infants because of the risk of severe infectious disease, NEC, and fatal outcome.  Further studies are necessary to investigate the pathogenesis of these effects and the possible prophylactic measures that could be taken to prevent them.